Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Living Cell Technologies ( (AU:1AI) ) is now available.
Algorae Pharmaceuticals announced the results of its Annual General Meeting, where all proposed resolutions were carried, including the adoption of the remuneration report and the approval of a 10% placement facility. These outcomes reflect strong shareholder support and are expected to facilitate the company’s strategic initiatives, including the expansion of its AI-driven drug discovery platform and the development of novel treatments.
More about Living Cell Technologies
Algorae Pharmaceuticals is an AI-enabled pharmaceutical development company focused on discovering and developing drug synergies for unmet medical needs. Utilizing its proprietary AI platform, AlgoraeOS, the company applies machine learning and deep neural networks to identify transformative therapeutic drug combinations. Algorae collaborates with research institutions and pharmaceutical partners to accelerate AI-predicted therapies into clinical stages and is publicly traded on the Australian Stock Exchange.
Average Trading Volume: 10,231,180
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$13.5M
For a thorough assessment of 1AI stock, go to TipRanks’ Stock Analysis page.